SCIENTIFIC REPORTS

OPEN

Received: 24 August 2016 Accepted: 10 October 2016 Published: 25 October 2016

Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations

Fariborz Mobarrez^{1,*}, Anna Vikerfors^{1,*}, Johanna T. Gustafsson¹, Iva Gunnarsson¹, Agneta Zickert¹, Anders Larsson², David S. Pisetsky³, Håkan Wallén⁴ & Elisabet Svenungsson¹

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by circulating autoantibodies and the formation of immune complexes. In these responses, the selecting self-antigens likely derive from the remains of dead and dying cells, as well as from disturbances in clearance. During cell death/activation, microparticles (MPs) can be released to the circulation. Previous MP studies in SLE have been limited in size and differ regarding numbers and phenotypes. Therefore, to characterize MPs more completely, we investigated 280 SLE patients and 280 individually matched controls. MPs were measured with flow cytometry and phenotyped according to phosphatidylserine expression (PS⁺/PS⁻), cellular origin and inflammatory markers. MPs, regardless of phenotype, are 2–10 times more abundant in SLE blood compared to controls. PS⁻ MPs predominated in SLE, but not in controls (66% vs. 42%). Selectively in SLE, PS⁻ MPs were more numerous in females and smokers. MP numbers decreased with declining renal function, but no clear association with disease activity was observed. The striking abundance of MPs, especially PS⁻ MPs, suggests a generalized disturbance in SLE. MPs may be regarded as "liquid biopsies" to assess the production and clearance of dead, dying and activated cells, i.e. pivotal events for SLE pathogenesis.

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the production of autoantibodies targeting nuclear and membrane molecules [i.e., antinuclear antibodies (ANA) and antiphospholipid antibodies (aPL)] in association with systemic and local inflammatory manifestations as well as premature vascular disease¹⁻³. Lupus primarily affects young women (90%) and, while its etiology is unknown, studies on patients and murine models suggest an important role in pathogenesis for disturbances in cell death as well as the clearance of dead and dying cells. These disturbances may increase the amount of circulating cellular debris which is believed to contain self-antigens (e.g., nucleosomes and DNA) that can trigger B-cells to produce autoantibodies in susceptible individuals⁴⁻⁶. While there has been extensive investigation on the molecular properties of the ANAs and aPLs, much less is known about the *in vivo* form of the nuclear antigens. Furthermore, there are few biomarkers that can assess the extent of *in vivo* cell death, tissue localization of dying cells and their clearance.

Among the products of dead and dying cells, microparticles (MPs) provide an important source of bioactive molecules that can induce a broad range of immunological and vascular activities; these particles can also provide a source of nuclear and membrane molecules to drive ANA and aPL production, eventually leading to immune complex formation^{7.8}. MPs are small membrane-bound vesicles, 0.1 to 1.0 microns in diameter, that can be released from cells undergoing cell activation as well as cell death. A major class of extracellular vesicles (EVs)

¹Unit of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. ²Department of Clinical Chemistry and Pharmacology, Akademiska Hospital, SE-751 85 Uppsala, Sweden. ³Department of Medicine, Duke University Medical Center; Medical Research Service, Durham VA Hospital, NC, USA. ⁴Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Division of Cardiovascular Medicine, Stockholm, Sweden. ^{*}These authors contributed equally to this work. Correspondence and requests for materials should be addressed to F.M. (email: fariborz.mobarrez@ki.se) in the blood, MPs can transmit information from one cell to another and modulate responses through their content of alarmins (e.g., HMGB1), lipid mediators and cytokines as well as nuclear autoantigens; MPs also display tissue factor, which can promote thrombosis^{9–11}. MPs are typically identified in terms of size by flow cytometry by light scatter and exposure of phosphatidylserine (PS), an "eat me signal" for the immune system, detected by staining with annexin-V or lactadherin; further characterization involves cell surface markers of the potential cells of origin (e.g., CD41 from platelets)^{12,13}.

Studies on the expression of MPs in lupus and related disorders have been of limited size and use a variety of analytic techniques for particle assessment. Together, these studies suggest that disturbances in MP expression in SLE are common and extensive although, in some instances, the conclusions of these studies have diverged. Thus, both higher and lower numbers of MPs in the blood of SLE patient compared to those in controls have been reported^{14,15}. Because of the value of MPs as biomarkers, we have characterized more completely MP expression in SLE through the flow cytometric analysis of blood from large and very well characterized cohort of consecutive SLE patients and compared these profiles to those of individually matched population controls. We further explored if the levels MPs are related to clinical and serological features of SLE.

Results

Clinical Characteristics of Patients. Basic clinical characteristics of the patients are presented in Table 1. Median disease duration was 13 years (IQR: 6-23 years). Active disease was considered present if SLAM index (disease activity measurement) was above 6 (49%)¹⁶.

Occurrence of Microparticles in Blood. Overall, the numbers of MPs measured in the blood were approximately 6 times greater in SLE patients than controls. MPs were initially sub-grouped as PS positive (PS⁺) or PS negative (PS⁻) particles, based on lactadherin binding. In SLE patients, PS⁻ MPs predominated (64%) and were approximately three times more common than PS⁺MPs (Supplementary Figure 1). In contrast, PS⁺ MPs were most common (64%) in controls. Thus, the majority of the MPs measured in the SLE samples are PS⁻ MPs (Fig. 1). We further characterized these MPs in terms of their expression of markers that may indicate a role in inflammation or thrombosis. For this purpose, we assessed the expression of tissue factor, VCAM-1, CD40L and HMGB1 on MPs. By other approaches, levels of these markers have all been shown to be elevated in the blood of SLE patients¹⁷⁻¹⁹. Of note, previous studies have shown that both sCD40L and HMGB1 can be MP components^{20,21}. The data presented in Fig. 2 indicate that these markers are expressed on both the PS⁻ and PS⁺ populations.

In a further comparison of the levels of the different MP phenotypes with those of individually matched controls, the data indicated that all MP populations, regardless of PS surface marker expression, are more abundant in SLE patients compared to controls (Fig. 2A,B). Platelet, endothelial and leukocyte derived MPs (PMPs, EMPs and LMPs) in blood of patients were approximately 2–7 times higher than those of controls. Activation and inflammation markers, such as CD40L, VCAM-1, TF and HMGB1, expressed on MPs were also much higher in SLE patients. The numbers of C4d-expressing PMPs and EMPs were approximately ten and five times higher, respectively, in SLE patients as compared to controls (Fig. 3). It is of note that measurement of C4d was not performed in the presence of lactadherin, as the reagents for the detection of these proteins are both conjugated with FITC dye. Thus, both PS⁺ and PS⁻ MPs were included when C4d-expressing MPs were counted.

Associations between microparticles levels and phenotype and SLE features. The levels of PS⁻ and PS⁺ MPs in SLE patients were investigated for associations with clinical and serological variables. In general, levels of PS⁻ MPs showed more convincing associations with SLE features as compared to PS⁺ MPs (significant level p < 0.01 and higher, Table 2 and Supplementary Tables 1 and 2). We chose to consider only associations that remained significant after Bonferroni correction (Table 2); however, in supplementary Table 1 and 2 all significant associations are shown. As these data indicate, levels of PS⁻ MPs were strongly associated with gender (more in females, Table 2) in SLE, while no gender association was observed among controls (Supplementary Tables 3 and 4). Levels of PS⁻ MPs were also associated with measures of renal function as well as with inflammatory markers; TNF- α , TNFR1 and 2, MCP-1 (Table 2). PS⁺ MPs were associated with disease duration (Table 2). Levels of EMPs expressing C4d were positively associated with smoking. Despite these findings, the levels of MPs were not significantly associated with disease activity as assessed by the SLAM¹⁶, suggesting that increased expression of MPs from many different cell types is common in the course of SLE but may not be directly related to disease activity.

Discussion

These studies provide new insights into the expression of MPs during SLE and demonstrate that, regardless of PS expression and phenotype, MPs occur in the blood of patients at levels 2 to 10 times greater than those of controls. In our studies, PS⁻ MPs were twice as common than PS⁺ MPs in SLE blood while, in controls, the distribution was reversed. Furthermore, MPs in SLE blood display pro-inflammatory and pro-coagulant molecules (e.g., sCD40L and TF) and can potentially promote the inflammation and thrombosis characteristic of SLE. Together, our results demonstrate widespread disturbances in MP expression among SLE patients and suggest that MP assessments could be valuable assay platforms for studies of cell turnover and development of new biomarkers in SLE.

Our findings build upon previous studies on particle expression in lupus^{14,22–24}. Thus, Nielsen *et al.* reported that PS⁻ MPs are more frequent in the blood of SLE patients compared to healthy controls, while PS⁺ MPs occurred at similar frequencies in SLE patients and controls¹⁵. In contrast, our study showed that the levels of both PS⁺ and PS⁻ MPs are increased in SLE blood. The differences in the results of these studies may relate to methodological issues, including the capabilities of different flow cytometers and the use of annexin-V compared to lactadherin to identify PS^{12,25}. Importantly, we found that the majority of the MPs in SLE blood are PS⁻ MPs,

	SLE	Controls	p
Number	280	280	ns
Age (mean \pm SD)	47.4 ± 14.7	47.6 ± 14.7	ns
Gender Female (n, %)	258 (92%)	259 (92%)	ns
Disease duration, years (median [25:75])	13 [6:23]	_	_
Smoking, Current (n, %)	57 (20%)	37 (13%)	< 0.05
Medication (at inclusion, if not otherwise	stated)	1	-
Prednisolone (n, %) Mean dose: 8.6 mg	161 (58%)	2 (1%)	<0.0001
Azathioprine	54 (19%)	_	_
Hydroxychloroquine	93 (33%)	_	_
Mycophenolate mofetil	17 (6%)	_	_
Rituximab (ever)	24 (9%)	_	_
Warfarin	43 (15%)	1 (1%)	<0.0001
Low dose Acetylsalicylic acid	51 (18%)	9 (3%)	<0.0001
Statins	34 (12%)	12 (4%)	<0.0001
Lupus Manifestations		1	_
Butterfly (n, %)	147 (53%)	0 (0%)	
Discoid (n, %)	56 (20%)	0 (0%)	_
Photosensitivity (n, %)	197 (70%)	51 (18%)	<0.0001
Oral ulcers (n, %)	97 (35%)	8 (3%)	<0.0001
Arthritis (n, %)	235 (84%)	10 (4%)	<0.0001
Pleuritis (n, %)	98 (35%)	2 (1%)	<0.0001
Pericarditis (n, %)	48 (17%)	0 (0%)	_
Serositis (n, %)	110 (39%)	2 (1%)	< 0.0001
Nephritis (n, %)	110 (39%)	1 (1%)	< 0.0001
Psychosis (n, %)	7 (3%)	2 (1%)	ns
Seizures (n. %)	30 (11%)	5 (2%)	< 0.0001
Leucopenia (n. %)	138 (49%)	3 (1%)	< 0.0001
Lymphopenia (n. %)	146 (52%)	2 (1%)	< 0.0001
Thrombocytopenia (n. %)	61 (22%)	2 (1%)	< 0.0001
Hemolytic anemia (n. %)	16 (6%)	1 (1%)	< 0.0001
aDNA ever (n. %)	193 (69%)	-	<0.001
aDruck, ever (n, %)	42 (15%)		
Immunological criteria (n. %)	200 (71%)		
SLAM $> 6 (n \%)$	137 (49%)		
Autoantibodies at Inclusion	157 (4570)		
deDNA (p. %)	101 (36%)	3 (1%)	< 0.0001
Nucleosemes (n. %)	101 (30%)	1 (0%)	<0.0001
Sm(n, 0)	52 (10%)	2 (0%)	<0.0001
BND68 (n. %)	32 (19%)	2 (0%)	<0.0001
	23 (970)	0 (0%)	<0.0001
SSA (II, 70)	64 (22%)	4 (1%) 0 (2%)	<0.0001
SSB (II, %)	64 (23%)	9 (5%)	<0.0001
Lupus anticoagulant (n, %)	63 (23%)		
Cardiolipin IgG (n, %)	53 (19%)		
Cardiolipin IgM (n, %)	23 (8%)		
Cardiolipin IgA (n, %)	45 (16%)		_
β_2 GP-1 IgG (n, %)	56 (20%)		
β_2 GP-1 lgM (n, %)	26 (9%)		
β_2 GP-1 IgA (n, %)	44 (16%)	_	
Inflammation Markers		0.5 5	
hs CRP (mg/L) (median [25:75])	1.5 [0.6:5.0]	0.9 [0.5:2.2]	<0.0001
C3 (g/L) (median [25:75])	0.86 [0.7:1.01]		-
C4 (g/L) (median [25:75])	0.14 [0.1:0.19]		-
Fibrinogen (g/L) (median [25:75])	3.9 [3.2:4.8]	3.8 [3.2:4.4]	ns
Creatinine (µmol/L) (median [25:75])	69 [59:84]	66 [59:74]	<0.0001
Cystatin C GFR (mL/min/1,73 m ²) (median [25:75])	76 [55:101]	108 [93:121]	<0.0001
IL-6 (ng/L) (median [25:75])	3.3 [2.2:6.3]		-
Continued			

	SLE	Controls	p		
TNFα (pg/L) (median [25:75])	1.8 [1.0:3.0]	—	_		
TNFR1 (pg/L) (median [25:75])	1697 [1279:2478]	1306 [1087:1564]	< 0.0001		
TNFR2 (pg/L) (median [25:75])	5200 [3851:8055]	3600 [2875:4300]	< 0.0001		
IP-10 (pg/L) (median [25:75])	199 [121:379]	72 [50:101]	< 0.0001		
MCP-1 (pg/L) (median [25:75])	184 [112:292]	72 [29:112]	< 0.0001		
Other Parameters					
APS (n, %)	47 (17%)	0 (0%)	_		
Any arterial event (n, %)	35 (13%)	3 (1%)	< 0.001		
Any vascular event (n, %)	68 (24%)	7 (2%)	< 0.001		
Venous thromboembolism (VTE) (n, %)	41 (15%)	4 (1%)	< 0.001		

Table 1. Basic clinical characteristics of SLE patients and controls. Distributions are given as % or median (interquartile range). Patients and matched controls were compared with paired tests; McNemar's test or paired t-test depending on data type. aDNA = anti-DNA antibody; aSM = Anti-Smith antibodies; SLAM = Systemic Lupus Activity Measure¹⁶; dsDNA = doublestranded DNA; ; Sm = Smith; RNP = ribonucleoprotein; SSA = Sjogrens syndrome antigen A; SSB = Sjogrens syndrome antigen B; β_2 GP-1 = beta₂glykoprotein-1; hsCRP = high sensitivity C reactive protein; C3/C4 = Complement factor 3/4; GFR = GFR - glomerular filtration rate; IL-6 = interleukin 6; TNF = Tumor necrosis factor; TNFR = Tumor necrosis factor receptor; IP10 = Interferon gamma-induced protein 10; MCP-1 = Monocyte Chemoattractant Protein-1. APS = Antiphospholipid syndrome, according to Miyakis *et al.*⁵³.





while in controls the majority are PS⁺. Thus, the use of PS expression to define MP numbers may give an incomplete picture of particle expression in SLE.

In our studies, PS⁻MPs in SLE were strongly associated with female gender, similar gender differences were not apparent in controls (Table 2). This is an interesting observation, which should be further investigated as a possible clue to understand the striking female predominance in SLE. The high numbers of PS⁻ MPs could result from masking of PS by other molecules such as β_2 GP1 and annexin-V which are abundant proteins in the circulation^{26,27}; both of these proteins can bind to PS. Autoantibodies against β_2 GP1 and/or annexin V are frequent in SLE^{6,28,29}; these antibodies could bind to PS⁺ MPs, thus preventing interaction with lactadherin. This possibility is consistent with studies demonstrating that MPs in SLE blood carry increased loads of immunoglobulins on their surface^{8,24}. Since PS is crucial for the recognition of apoptotic material by phagocytes, increased number of



Figure 2. Number and phenotype of lactadherin positive (A) or lactadherin negative (B) microparticles in SLE patients and matched controls. Microparticles in SLE (n = 280) and matching controls (n = 280) were detected by flow cytometry and defined as particles less than 1.0 μ m in size and either positive for lactadherin (A) or negative for lactadherin (B). Each subpopulation was then phenotyped according to origin or expression of inflammation/activation markers. Dark grey = SLE patients; light grey = matching controls; PMPs = platelet microparticles; EMPs = endothelial microparticles; LMPs = leukocyte microparticles; MMPs = monocyte microparticles; CD40L = Cd40 ligand; TF = tissue factor; VCAM-1 = Vascular cell adhesion protein 1; HMGB1 = High mobility group box 1. Each group (patients vs. controls) was compared with t-test after log transformation of data. Bars represent median values and Platelet microparticles and endothelial microparticles expressing complement *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.001.

PS⁻ MPs in SLE could persist unrecognized in the circulation, promoting inflammation and thrombosis as well as serving as sources of autoantigens to drive responses or form immune complexes^{7,30,31}.

Platelet MPs were the most abundant particle type both in patients and controls. Furthermore, our data show that PMPs displaying CD40L are more numerous in SLE, regardless of PS expression (Fig. 2A,B). Platelets are the main source of CD40L, producing >90% of soluble CD40L (sCD40L) in blood³². As PMPs carry CD40L from the site of platelet activation, they could promote activation of cells in the periphery as well as the immediate surroundings. We have recently demonstrated that assay of CD40L positive MPs may represent a more sensitive approach for sCD40L determinations compared to ELISA assays, suggesting that assay of "soluble' markers on particles may represent a useful analytic approach²¹. Relevance of such assessment comes from studies indicating that levels of CD40L on immune cells as well as sCD40L are increased in SLE and links to disease activity and activation of B-cells and the type I IFN system have been reported³³⁻³⁵.

As our results showed, the total number of EMPs and EMPs expressing VCAM-1 and TF were increased in both PS⁺ and PS⁻ MPs. We have previously reported that circulating VCAM-1 levels can predict cardiovascular



Figure 3. Platelet microparticles and endothelial microparticles expressing complement factor 4d in SLE patients and matched controls. Microparticles in SLE and matching controls were detected by flow cytometry and defined as particles less than $1.0\,\mu$ m in size and positive for either CD41 (platelet origin) or CD144 (endothelial origin). Later, the expression of complement factor 4d was measured in each subpopulation. PMPs = platelet microparticles; EMPs = endothelial microparticles; C4d = complement factor 4d. Each group (patients vs. controls) was compared with t-test after log transformation of data. Bars represent median values and line indicates interquartile range (25th and 75th percentile). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.001.

	PS negative MPs	PS positive MPs
Gender Female (n = 280)	[+] Total PS negative MPs (***) [+] PMPs (*)	
Smoking current (n = 280)	[+] EMPs ^{C4d} (*)	[+] EMPs ^{VCAM1} (*)
Inflammation Markers	·	
Cystatin C GFR (n=271)	[+] Total PS negative MPs (***) [+] PMPs (*)	
TNF-a (n = 207)	[-] Total PS negative MPs (*)	
TNFR1 (n = 275)	[-] Total PS negative MPs (**) [-] PMPs (*)	
TNFR2 (n = 276)	[-] Total PS negative MPs (*)	
MCP-1 (n = 275)	[+] LMPs (*)	

Table 2. Associations between Microparticles and SLE features in 280 SLE patients. Values are given as direction [+/-] and MP phenotype followed by asterisk: ***p < 0.001, **p < 0.01, *p < 0.05. p-values (t-test) represent adjustment according to Bonferroni test. Blank = non significant (p-value > 0.05). GFR = glomerular filtration rate; TNF = Tumor necrosis factor; TNFR = Tumor necrosis factor receptor; MCP-1 = Monocyte Chemoattractant Protein-1.

events and cardiovascular mortality in SLE^{36,37}, but the present study is the first to demonstrate increased numbers of EMPs expressing VCAM-1 in SLE. These results are consistent with those other studies indicating ongoing endothelial activation in SLE³⁸. The finding of enhanced TF expression on both EMPs and leukocyte MPs, together with previous reports of increased levels of soluble TF in SLE³⁹, could indicate an active role of TF positive MPs in thrombosis; functional measurements of particles, however, are needed to evaluate this possibility. In this regard, we previously demonstrated that MPs can promote thrombin formation by both exposing PS (offers a binding site for coagulation factors) and by expressing TF⁴⁰.

In the current study, we detected approximately ten times more C4d⁺ PMPs and five times more C4d⁺ EMPs in patients than in controls. The increased number of MPs expressing C4d in SLE points to ongoing complement activation in lupus. This is also consistent with observations indicating the utility of erythrocyte and platelet-bound C4d levels as a biomarker associated with all-cause mortality, vascular events, and aPL^{41,42}. The presence of C4d on particles could result from their role as a source of self-antigen to form immune complexes. Related studies have demonstrated the presence of IgG-positive particles in blood of patients as well as the ability of serum antibodies to bind to particles generated *in vitro*^{8,24}.

The prototype alarmin HMGB1 is a non-histone nuclear protein with diverse immunological activities. Both cell death and immune cell activation can lead to the translocation of HMGB1 from the nucleus into the cytoplasm and the extracellular space. High levels HMGB1 are present in the blood of SLE patients and associated with higher disease activity⁴³⁻⁴⁵. The data presented herein demonstrate a high frequency of MMPs with HMGB1 in SLE. In a previous study, LPS administration to volunteers induced increased numbers of particles with HMGB1²⁰. These results suggest that, during inflammation MPs may be a source of extracellular HMGB1, which can be quantified in blood. As suggested in other studies, the concentration of HMGB1 molecules in proximity with other cytokines on a particle surface could increase immune activity by allowing interaction with multiple receptors simultaneously^{46,47}.

In assessing clinical association of MP levels in SLE, we found more robust clinical associations with PS⁻ MPs than PS⁺ MPs. In accord with some previous studies^{14,23}, we did not find convincing associations with disease activity. The lack of a relationship between particle numbers and disease activity could relate to the variety of clinical manifestations assessed by an instrument such as the SLAM and their weighting; furthermore, MPs may play a role in some but not all features of lupus. Since our study was cross-sectional in design, we cannot exclude a stronger association with disease activity in individual patients over time. Nevertheless, the elevation of MPs during putatively inactive disease in some patients may also suggest that current instruments do not adequately reflect disease activity.

While we did not show a relationship of MP levels to disease activity, we did demonstrate that declining renal function is associated with fewer numbers of PS⁻ MPs and PS⁻ PMPs. A recent study demonstrated that galactin-3 binding protein, a component of MPs, can co-localize with immune complexes in renal biopsies; these findings suggest that MPs can be deposited in renal tissue and serve as a source of immune complexes to drive events in lupus nephritis⁴⁸. We also observed strong positive associations between the number of PMPs expressing CD40L and levels of TNFR1 and/or TNFR2. All of which belongs to the tumor necrosis factor receptor superfamily, whose expression may increase during inflammation and apoptosis. TNFRs have also been associated with disease activity in SLE, in particular with active nephritis^{49,50}. Two recent *in vitro* studies have reported that particles can induce NETosis as well as the production of INF- α and other pro-inflammatory cytokines^{38,51}. Further studies are needed to understand how particles relate to the different phases of SLE activity.

In conclusion, in this large study, we report striking differences in numbers of various particle types in the blood of SLE patients and matched controls; we also report skewed relative distribution of PS⁻ and PS⁺ MPs. Together, these findings point to widespread disturbances in SLE in the processes generating and clearing MPs and suggest that MP measurement should be explored as a component of "liquid biopsies" to evaluate the ongoing events in the course of SLE.

Methods

Study population and clinical data. In this cross-sectional study we included 280 consecutive SLE patients, who received care at the Department of Rheumatology, Karolinska University Hospital 2004-2011. All patients fulfilled at least four of the 1982 revised classification criteria for SLE according to the American College of Rheumatology³ were asked to participate. We used no exclusion criteria. 280 "SLE-free" population controls were individually matched to the SLE patients for age, sex and region of living. Controls were identified in the Swedish national population registry, contacted by letter and asked to participate. A rheumatologist interviewed and examined all participants. Medical records were reviewed. Organ manifestations were defined according to criteria³. SLE disease activity was assessed with the SLAM¹⁶ and organ damage with Systemic Lupus International Collaborating Clinics/ACR Damage index (SLICC/ACR-DI)⁵². Myocardial infarction (MI), ischaemic heart disease (IHD, including MI and/or angina), ischaemic stroke, venous thromboembolism (VTE, including venous thromboembolism and/or pulmonary embolism) were verified as previously described⁵³. The APS was defined according to Miyakis et al., with the exception that not all aPL tests were performed within five years of the clinical event⁵⁴. On the morning of clinical assessment blood samples were drawn into citrated tubes after overnight fasting and centrifuged within 1 hour at 2570 g for 20 min in room temperature (RT) and subsequently stored at -80° as platelet-poor plasma (PPP). The local ethic committee at Karolinska University Hospital approved the study and all the experiments were performed in compliance with good clinical practice and good laboratory practice. All study subjects gave written informed consent to participate.

Laboratory tests including aPL and lupus anticoagulant. High-sensitivity (hs) CRP, fibrinogen, albumin and creatinine were measured with BN ProSpec System (Dade Behring, Deerfield, IL, USA). Complement factor 3 and 4 (C3 and C4) were analyzed using IMMAGETM system (Beckman Coulter, Brea, CA, USA). Cystatin C was analyzed on Architect Ci8200 analyzer with cystatin C reagents from Gentian (Moss, Norway). Levels of TNFR1 (DY225), TNFR2 (DY726), VCAM (DY809), IP10 (DY266), and MCP-1 (DY279) were analyzed with commercial sandwich ELISA kits (R&D Systems, Minneapolis, MN, USA). Estimated (e) glomerular filtration rate (GFR) was calculated from serum cystatin C (eGFRcystatin C) results in mg/L as previously described⁵⁵. Other variables were determined by routine clinical tests. Antinuclear antibodies (ANA) were analysed by indirect immunofluorescence (IFL) on HEp-2 cells (Immunoconcepts, Sacramento, CA, USA). Antibodies to specific nuclear antigens (dsDNA, SSA-Ro52, SSA-Ro60, SSB, Sm) and phospholipids (cardiolipin IgG, IgM, IgA and β_2 -glycoprotein1 IgG, IgM, IgA) were analysed by multiplexed bead technology (Luminex) using BioPlex 2200 system (Bio-Rad, Hercules, CA, USA) according to the specifications of the manufacturer. The cut-off for anti-cardiolipin (aCL) and anti- β_2 -glycoprotein1 (a β_2 GP1) fulfills the 99th percentile as described⁵⁴. LA was determined using a modified Dilute Russell Viper Venom method (Biopool, Umea, Sweden) using Bioclot lupus anticoagulant. In February 2010, a new test procedure using two integrated tests (one dRRVT and one APTT) became routine. Less than 5% of the samples were analyzed according to this procedure.

Measurement of MPs. PPP was thawed in a water bath for approximately 5 minutes (37 °C) and then centrifuged at 2000g for 20 min at RT, in order to further remove any debris or cells that may interfere with the analysis. The supernatant was then re-centrifuged at 13000g for 2 min at RT. Subsequently, 20μ L of the supernatant (which contains the MPs) were incubated for 20 minutes in the dark with phalloidin-Alexa 660 (cell-fragment marker, Invitrogen, Paisley, UK)⁵⁶, lactadherin-FITC (binds to PS, Haematologic Technologies, VT, USA) and either CD41-PE (platelet MP; PMPs, abcam, Cambridge, UK), CD45-PC7 (leukocyte MP; LMPs, Beckman Coulter, Brea, CA, USA) or CD144-APC (endothelial MPs; EMPs, AH diagnostics, Stockholm, Sweden). In addition,

exposure of CD142-PE (tissue factor; TF, BD, NJ, USA) was measured on EMPs and LMPs, CD40 Ligand (L) (CD154; BD, San Jose, CA, USA) on PMPs, vascular cell adhesion molecule 1 (VCAM-1; CD106-PE, AH diagnostics, Stockholm, Sweden) on EMPs, high-mobility group protein B1 (HMGB1; R&D Systems, Minneapolis, USA) on monocyte MPs (MMPs, CD14-PC7, Beckman Coulter, Brea, CA, USA) and C4d (anti-C4d-FITC, ALPCO Diagnostics, Salem, NH, USA) on PMPs and EMPs. MPs were measured by flow cytometry on a Beckman Gallios instrument (Beckman Coulter, Brea, CA, USA). The MP gate was determined using Megamix beads (0.5–3.0 μ m, BioCytex, Marseille) (Fig. 2 in supplementary). MPs were defined as particles less than 1.0 μ m in size (as MPs are between 0.1–1.0 μ m in diameter) and positive or negative to lactadherin and cell markers as described above, i.e. two populations of MPs based on PS expression. Conjugate isotype-matched immunoglobulins with no reactivity against human antigens were used as negative controls. In the present study, results are shown as numbers of MPs (MP counted x standard beads added/L)/standard beads counted (FlowCount, Beckman Coulter, CA, USA). The intra- and interassay coefficients of variation for MP measurement were less than 9% respectively.

Statistical analysis. Prior to statistical analysis, data were log transformed, if necessary, to obtain a normal distribution. Patients and matched controls were compared with paired tests; McNemar's test or paired t-test depending on data type. Within the patient and control group, associations between MPs levels and clinical/laboratory characteristics were investigated with linear regression or t-test, and results are reported as p-value and direction of association. The Bonferroni correction was used to adjust for multiple comparisons (Table 2 and Supplementary Tables 1–4). Statistical analysis was performed using JMP software (SAS Institute, v12.0, Cary, North Carolina, USA).

References

- 1. Lisnevskaia, L., Murphy, G. & Isenberg, D. Systemic lupus erythematosus. Lancet 384, 1878–1888 (2014).
- 2. Gatto, M. et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmunity Reviews 12, 523–536 (2013).
- 3. Tan, E. M. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism 25, 1271-1277 (1982).
- 4. Colonna, L., Lood, C. & Elkon, K. B. Beyond apoptosis in lupus. Current Opinion in Rheumatology 26, 459-466 (2014).
- Muñoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A. & Herrmann, M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6, 280–289 (2010).
- 6. Andreoli, L. et al. Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity 46, 302-306 (2013).
- 7. Sisirak, V. et al. Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell 166, 88–101 (2016).
- 8. Nielsen, C. T. et al. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis & Rheumatism 64, 1227–1236 (2012).
- 9. Beyer, C. & Pisetsky, D. S. The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 6, 21–29 (2010).
- Owens, A. P. & Mackman, N. Microparticles in hemostasis and thrombosis. *Circulation Research* 108, 1284–1297 (2011).
 Cloutier, N. *et al.* The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. *EMBO Mol Med* 5, 235–249 (2012).
- Dasgupta, S. K., Guchhait, P. & Thiagarajan, P. Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Translational Research 148, 19–25 (2006).
- Lacroix, R., Robert, S., Poncelet, P. & Dignat-George, F. Overcoming limitations of microparticle measurement by flow cytometry. Semin. Thromb. Hemost. 36, 807–818 (2010).
- 14. Pereira, J. *et al.* Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. *Thromb Haemost* **95**, 94–99 (2006).
- Nielsen, C. T., Østergaard, O., Johnsen, C., Jacobsen, S. & Heegaard, N. H. H. Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis & Rheumatism 63, 3067–3077 (2011).
- Liang, M. H., Socher, S. A., Roberts, W. N. & Esdaile, J. M. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis & Rheumatism 31, 817-825 (1988).
- 17. Spronk, P. E., Bootsma, H., Huitema, M. G., Limburg, P. C. & Kallenberg, C. G. M. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. *Clin Exp Immunol* **97**, 439–444 (2008).
- Goules, A. et al. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. Journal of Autoimmunity 26, 165–171 (2006).
- 19. Adams, M. J., Palatinus, A. A., Harvey, A. M. & Khalafallah, A. A. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus. *lupus* **20**, 1474–1483 (2011).
- Soop, A. *et al.* Effect of lipopolysaccharide administration on the number, phenotype and content of nuclear molecules in blood microparticles of normal human subjects. *Scand J Immunol* 78, 205–213 (2013).
- Mobarrez, F. et al. CD40L expression in plasma of volunteers following LPS administration: A comparison between assay of CD40L on platelet microvesicles and soluble CD40L. Platelets 26, 486–490 (2015).
- Parker, B. et al. Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Annals of the Rheumatic Diseases 73, 1144–1150 (2014).
- 23. Sellam, J. et al. Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res. Ther. 11, R156 (2009).
- 24. Ullal, A. J. et al. Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. Journal of Autoimmunity 36, 173–180 (2011).
- Lacroix, R. et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 8, 2571–2574 (2010).
- 26. de Groot, P. G. & Urbanus, R. T. The significance of autoantibodies against β2-glycoprotein I. *Blood* **120**, 266–274 (2012).
- Hamdan, R., Maiti, S. N. & Schroit, A. J. Interaction of beta2-glycoprotein 1 with phosphatidylserine-containing membranes: liganddependent conformational alterations initiate bivalent binding. *Biochemistry* 46, 10612–10620 (2007).
- Reshetniak, T. M. et al. [Antibodies to beta2-glycoprotein I in systemic lupus erythematosus: new laboratory marker of antiphospholipid syndrome]. Klin Med (Mosk) 76, 36–40 (1998).
- 29. Iaccarino, L. *et al.* Anti-annexins autoantibodies: Their role as biomarkers of autoimmune diseases. *Autoimmunity Reviews* **10**, 553–558 (2011).
- Ardoin, S. P., Shanahan, J. C. & Pisetsky, D. S. The role of microparticles in inflammation and thrombosis. Scand J Immunol 66, 159–165 (2007).
- Pisetsky, D. S., Ullal, A. J., Gauley, J. & Ning, T. C. Microparticles as mediators and biomarkers of rheumatic disease. *Rheumatology* (Oxford) 51, 1737–1746 (2012).

- 32. Habets, K. L. L., Huizinga, T. W. J. & Toes, R. E. M. Platelets and autoimmunity. Eur J Clin Invest 43, 746-757 (2013).
- 33. Kato, K. et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. 104, 947–955 (1999).
- Henn, V. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591–594 (1998).
 Duffau, P. et al. Platelet CD154 Potentiates Interferon- Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus. Science Translational Medicine 2, 47ra63–47ra63 (2010).
- 36. Gustafsson, J. et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus a prospective cohort study. Arthritis Res. Ther. 11, R186 (2009).
- 37. Gustafsson, J. T. et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res. Ther. 14, R46 (2012).
- Dieker, J. et al. Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosis. Arthritis Rheumatol 68, 462–472 (2016).
- 39. Nojima, J. et al. Tissue factor expression on monocytes induced by anti-phospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. *Biochem. Biophys. Res. Commun.* **365**, 195–200 (2008).
- 40. Mobarrez, F. *et al.* Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on plateletderived microparticles in patients with peripheral arterial occlusive disease. *Thromb Haemost* **106**, 344–352 (2011).
- 41. Ahearn, J. M., Liu, C.-C., Kao, A. H. & Manzi, S. Biomarkers for systemic lupus erythematosus. *Translational Research* 159, 326–342 (2012).
- 42. Lood, C. *et al.* Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus a possible link to venous thrombosis? *lupus* 21, 1423–1432 (2012).
- Andersson, U. & Harris, H. E. The role of HMGB1 in the pathogenesis of rheumatic disease. *Biochim. Biophys. Acta* 1799, 141–148 (2010).
- 44. Ma, C.-Y. *et al.* Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. *Rheumatol Int* **32**, 395–402 (2010).
- 45. Zickert, A. *et al.* Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. *Arthritis Res. Ther.* 14, R36 (2012).
- Hreggvidsdottir, H. S. et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. Journal of Leukocyte Biology 86, 655–662 (2009).
- 47. Schiraldi, M. *et al.* HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. *J. Exp. Med.* **209**, 551–563 (2012).
- Nielsen, C. T. et al. Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis. lupus 24, 1150–1160 (2015).
- Studnicka-Benke, A. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. *Rheumatology* 35, 1067–1074 (1996).
- 50. Svenungsson, E. *et al.* Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor α/tumor necrosis factor receptor system in systemic lupus erythematosus. *Arthritis* & *Rheumatism* **48**, 2533–2540 (2003).
- 51. Niessen, A. *et al.* Apoptotic-cell-derived membrane microparticles and IFN-α induce an inflammatory immune response. *J. Cell. Sci.* **128**, 2443–2453 (2015).
- 52. Gladman, D. D. & Urowitz, M. B. The SLICC/ACR damage index: progress report and experience in the field. *lupus* **8**, 632–637 (1999).
- 53. Gustafsson, J. T. et al. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases 74, 1537–1543 (2015).
- 54. Miyakis, S. *et al.* International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* **4**, 295–306 (2006).
- Jonsson, A.-S., Flodin, M., Hansson, L.-O. & Larsson, A. Estimated glomerular filtration rate (eGFRCystC) from serum cystatin C shows strong agreement with iohexol clearance in patients with low GFR. Scand J Clin Lab Invest 67, 801–809 (2007).
- 56. Mobarrez, F. et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thrombosis Research 125, e110–e116 (2010).

Acknowledgements

We are grateful to Sonia Möller, Susanne Pettersson, Eva Jemseby, Gull-Britt Almgren, Gloria Rostvall, Julia Boström, Katherina Aguilera and Martin Olt for blood sampling and laboratory assistance. We are grateful for funding from the Swedish Research Council, the Swedish Heart-Lung Foundation, ALF funding from Stockholm County Council and Karolinska Institutet, the Swedish Rheumatism Association, the King Gustaf V 80th Birthday Fund, the Swedish Society of Medicine, the Foundation in memory of Clas Groschinsky and Karolinska Institutet Foundations.

Author Contributions

E.M. designed the flow cytometric panels, analyzed the MP samples, interpreted the results, performed statistical analysis, drafted, revised and finalized the manuscript. A.V. interpreted the results, performed statistical analysis, drafted, revised the manuscript. J.G. and A.Z. were involved in inclusion of patients and controls. I.V. was also involved in inclusion of patients and controls and critically revised the manuscript. A.L. performed some laboratory analysis and critically revised the manuscript. D.P. and H.W. participated in the design of the study, interpretation of data, major revisions and finalized the manuscript. E.S. was involved in the design of the study, inclusion of patients and controls, interpretation of data, performed statistical analysis, drafted, revised and finalized the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Mobarrez, F. *et al.* Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations.. *Sci. Rep.* **6**, 36025; doi: 10.1038/ srep36025 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016